First described in 1981, cancer antigen (CA) 125 in ovarian cancer was the first biomarker for cancer diagnosis and surveillance approved by the US Food and Drug Administration.1,2 Cancer antigen 125 is produced by ovarian cancer cells and detectable in the serum through a blood draw. Here, MUC16 is linked to ovarian carcinoma.